Dr Stephen Ryder

Dr Stephen Ryder

Queens Medical Centre Campus, Derby Road, Nottingham, NG7 2UH

View full bio
Consultant Physician in Hepatology and Gastroenterology
Studies
Title Start Date Status
IL-1 Signal Inhibition in Alcoholic Hepatitis 28th May 2019 Active
A phase I, randomised, double-blind, placebo-controlled, multi-centre, ascending-dose trial to evalu 1st May 2016 Active
Does addition of metformin to standard combination therapy increase sustained response rates for pat 1st August 2011 Ended
Ancillary study evaluating ChAd155-hIi-HBV shedding in a subset of chronic hepatitis B patients enro 19th February 2020 Active
An open label single arm study to investigate the safety and efficacy of multiple administartions of 1st September 2011 Ended
A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, an 21st May 2018 Active
A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week t 10th July 2018 Active
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) 2nd March 2017
Publications
Title
Fast-food hyper-alimentation and exercise restriction in healthy subjects
Prediction of liver disease in patients whose liver function tests have been checked in primary care
Autoantibodies in chronic hepatitis C virus infection and their association with disease profile
Chronic hepatitis C - what do the new drugs offer and who should get them first?
Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal
Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom populati
Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic
Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiv
The long-term prognosis of Alcoholic Hepatitis is poor and independent of disease severity for patie
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on
Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primar
Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis i
An analysis of rebleeding rates for variceal haemorrhage at a regional centre: what is the applicabi
Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary
Commentary: elastography as a predictor of portal hypertension
NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholan
Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute varice
Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widesprea
In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and
ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment
Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treat
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirr
The hepatitis C revolution part 1: antiviral treatment options
Effectiveness of a nurse-led alcohol liaison service in a secondary care medical unit
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steat
The Road to a Successful Transjugular Intrahepatic Portosystemic Shunt (Tips) Service: Experience of
The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches. Current op
Screening for hepatocellular carcinoma: patient selection and perspectives
Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis i
Become a Volunteer

Click here to find out how you can participate in our clinical trials
Patient & Public Involvement

Find out how you can help the Nottingham BRC to shape our research trials